Tubulis disclosed early clinical data showing a 59% overall response rate for its NaPi2b‑targeting ADC TUB‑040 across multiple dose cohorts in platinum‑resistant ovarian cancer and advanced non‑small cell lung cancer. The result was released shortly after the company closed a $361 million Series C, underlining investor appetite for its Tubutecan payload and P5 conjugation technology. The data set included heavily pretreated patients and showed activity at low doses, giving Tubulis a wide therapeutic window for dosing flexibility. Safety signals—most notably neutropenia—were consistent with ADC class effects. Tubulis plans to expand clinical testing based on the favorable early efficacy and tolerability profile.